1型人类免疫缺陷病毒体外感染联合化疗中交替用药与持续用药方案的比较
Alternating versus continuous drug regimens in combination chemotherapy of human immunodeficiency virus type 1 infection in vitro.
作者信息
Mazzulli T, Rusconi S, Merrill D P, D'Aquila R T, Moonis M, Chou T C, Hirsch M S
机构信息
Infectious Disease Unit, Massachusetts General Hospital, Harvard Medical School, Boston 02114.
出版信息
Antimicrob Agents Chemother. 1994 Apr;38(4):656-61. doi: 10.1128/AAC.38.4.656.
Abstract
We compared the in vitro efficacies of two-, three-, and four-drug combinations given continuously or in alternating regimens against a clinical isolate of human immunodeficiency virus type 1. In H9 cells and peripheral blood mononuclear cells, at the drug concentrations used in this study, there was greater suppression of human immunodeficiency virus type 1 infection as the number of drugs in the regimen was increased from one to four simultaneously administered agents. Although alternating drug regimens were effective, they were not better than continuous administration of either single drugs or combinations of agents and were less effective than giving all drugs of an alternating regimen simultaneously.
摘要
我们比较了持续给药或交替给药的两种、三种和四种药物组合对1型人类免疫缺陷病毒临床分离株的体外疗效。在H9细胞和外周血单核细胞中，在本研究使用的药物浓度下，随着方案中同时给药的药物数量从一种增加到四种，对1型人类免疫缺陷病毒感染的抑制作用增强。尽管交替给药方案有效，但它们并不比单一药物或药物组合的持续给药更好，并且比同时给予交替给药方案中的所有药物效果更差。
相似文献
1
Alternating versus continuous drug regimens in combination chemotherapy of human immunodeficiency virus type 1 infection in vitro.1型人类免疫缺陷病毒体外感染联合化疗中交替用药与持续用药方案的比较
Antimicrob Agents Chemother. 1994 Apr;38(4):656-61. doi: 10.1128/AAC.38.4.656.
2
Effect of resistance on combination chemotherapy for human immunodeficiency virus infection.
Adv Enzyme Regul. 1993;33:27-36. doi: 10.1016/0065-2571(93)90007-z.
3
Sequential versus simultaneous combination antiretroviral regimens for the treatment of human immunodeficiency virus type 1 infection in vitro.序贯与同步联合抗逆转录病毒疗法在体外治疗1型人类免疫缺陷病毒感染中的应用
J Infect Dis. 1997 Aug;176(2):510-4. doi: 10.1086/517277.
4
Inhibition of human immunodeficiency virus type 1 replication in cytokine-stimulated monocytes/macrophages by combination therapy.联合疗法对细胞因子刺激的单核细胞/巨噬细胞中人类免疫缺陷病毒1型复制的抑制作用。
J Infect Dis. 1994 Dec;170(6):1361-6. doi: 10.1093/infdis/170.6.1361.
5
New developments in combination chemotherapy of anti-human immunodeficiency virus drugs.抗人类免疫缺陷病毒药物联合化疗的新进展。
Ann N Y Acad Sci. 1990;616:318-27. doi: 10.1111/j.1749-6632.1990.tb17852.x.
6
Three-drug synergistic inhibition of HIV-1 replication in vitro by zidovudine, recombinant soluble CD4, and recombinant interferon-alpha A.
J Infect Dis. 1990 Jun;161(6):1059-67. doi: 10.1093/infdis/161.6.1059.
7
[Early antiretroviral combination therapy--standard today and tomorrow].[早期抗逆转录病毒联合疗法——当下及未来的标准]
Dtsch Med Wochenschr. 1997 Mar 14;122(11 Suppl):1-4.
8
Cyclobut-A and cyclobut-G, carbocyclic oxetanocin analogs that inhibit the replication of human immunodeficiency virus in T cells and monocytes and macrophages in vitro.环丁烷 -A和环丁烷 -G，即碳环氧丁酰肌苷类似物，可在体外抑制人类免疫缺陷病毒在T细胞、单核细胞和巨噬细胞中的复制。
Antimicrob Agents Chemother. 1990 Feb;34(2):287-94. doi: 10.1128/AAC.34.2.287.
9
Evaluation of Drug-Drug Interactions Between Hepatitis C Antiviral Agents Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and HIV-1 Protease Inhibitors.丙型肝炎抗病毒药物奥比他韦、帕利瑞韦/利托那韦和达沙布韦与HIV-1蛋白酶抑制剂之间的药物相互作用评估。
Clin Infect Dis. 2016 Apr 15;62(8):972-9. doi: 10.1093/cid/civ1213. Epub 2016 Jan 5.
10
Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides.对奥沙硫杂环戊烷胞嘧啶核苷耐药的人类免疫缺陷病毒的特性分析
Antimicrob Agents Chemother. 1993 Apr;37(4):875-81. doi: 10.1128/AAC.37.4.875.
引用本文的文献
1
Laser ablation for pharmaceutical nanoformulations: Multi-drug nanoencapsulation and theranostics for HIV.激光烧蚀法用于药物纳米制剂：HIV 的多药物纳米囊封和治疗诊断一体化。
Nanomedicine. 2020 Apr;25:102172. doi: 10.1016/j.nano.2020.102172. Epub 2020 Feb 13.
2
Favorable interactions between enfuvirtide and 1-beta-D-2,6-diaminopurine dioxolane in vitro.恩夫韦肽与1-β-D-2,6-二氨基嘌呤二氧戊环在体外的良好相互作用。
Antimicrob Agents Chemother. 2003 Nov;47(11):3644-6. doi: 10.1128/AAC.47.11.3644-3646.2003.
3
Anti-human immunodeficiency virus interactions of SCH-C (SCH 351125), a CCR5 antagonist, with other antiretroviral agents in vitro.CCR5拮抗剂SCH-C（SCH 351125）与其他抗逆转录病毒药物在体外的抗人类免疫缺陷病毒相互作用。
Antimicrob Agents Chemother. 2002 May;46(5):1336-9. doi: 10.1128/AAC.46.5.1336-1339.2002.
4
Nevirapine: a review of its use in the prevention and treatment of paediatric HIV infection.奈韦拉平：关于其在儿童HIV感染预防和治疗中应用的综述。
Paediatr Drugs. 2000 Sep-Oct;2(5):373-407. doi: 10.2165/00128072-200002050-00005.
5
Zalcitabine. An update of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of HIV infection.扎西他滨。其药效学和药代动力学特性以及在治疗HIV感染中的临床疗效的最新情况。
Drugs. 1997 Jun;53(6):1054-80. doi: 10.2165/00003495-199753060-00009.
6
Treatment of HIV infection. Tolerability of commonly used antiretroviral agents.HIV感染的治疗。常用抗逆转录病毒药物的耐受性。
Drug Saf. 1996 Sep;15(3):176-87. doi: 10.2165/00002018-199615030-00003.
7
Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors.1型人类免疫缺陷病毒的病毒背景在对蛋白酶抑制剂耐药性的产生中起主要作用。
Proc Natl Acad Sci U S A. 1996 Feb 20;93(4):1648-53. doi: 10.1073/pnas.93.4.1648.
8
Antiviral therapy for human immunodeficiency virus infections.人类免疫缺陷病毒感染的抗病毒治疗。
Clin Microbiol Rev. 1995 Apr;8(2):200-39. doi: 10.1128/CMR.8.2.200.
本文引用的文献
1
Nucleoside analogs: similarities and differences.核苷类似物：异同之处
Clin Infect Dis. 1993 Feb;16 Suppl 1:S7-15. doi: 10.1093/clinids/16.supplement_1.s7.
2
Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells.叠氮胸苷、双脱氧胞苷和双脱氧肌苷在静息和活化外周血单个核细胞中的磷酸化差异
J Clin Invest. 1993 May;91(5):2326-33. doi: 10.1172/JCI116463.
3
Alternating and intermittent regimens of zidovudine and dideoxycytidine in patients with AIDS or AIDS-related complex.齐多夫定与双脱氧胞苷交替及间歇用药方案治疗艾滋病或艾滋病相关综合征患者。
Ann Intern Med. 1993 Mar 1;118(5):321-30. doi: 10.7326/0003-4819-118-5-199303010-00001.
4
A randomized pilot study of alternating or simultaneous zidovudine and didanosine therapy in patients with symptomatic human immunodeficiency virus infection.一项针对有症状的人类免疫缺陷病毒感染患者进行齐多夫定与去羟肌苷交替或联合治疗的随机试点研究。
J Infect Dis. 1994 Jan;169(1):9-17. doi: 10.1093/infdis/169.1.9.
5
pol mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivo.赋予齐多夫定和去羟肌苷耐药性且在体外具有不同效应的pol突变，在体内产生多重耐药的1型人类免疫缺陷病毒分离株。
Antimicrob Agents Chemother. 1993 Jul;37(7):1480-7. doi: 10.1128/AAC.37.7.1480.
6
Inhibition of human immunodeficiency virus type 1 replication in vitro by the bisheteroarylpiperazine atevirdine (U-87201E) in combination with zidovudine or didanosine.
J Infect Dis. 1993 Aug;168(2):318-26. doi: 10.1093/infdis/168.2.318.
7
U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication.U - 90152，一种强效的1型人类免疫缺陷病毒复制抑制剂。
Antimicrob Agents Chemother. 1993 May;37(5):1127-31. doi: 10.1128/AAC.37.5.1127.
8
Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy.利用HIV-1多药耐药性的进化局限性优化治疗。
Nature. 1993 Feb 18;361(6413):650-4. doi: 10.1038/361650a0.
9
Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.剂量-效应关系的定量分析：多种药物或酶抑制剂的联合效应
Adv Enzyme Regul. 1984;22:27-55. doi: 10.1016/0065-2571(84)90007-4.
10
Synergistic inhibition of human immunodeficiency virus in vitro by azidothymidine and recombinant alpha A interferon.叠氮胸苷与重组αA干扰素在体外对人类免疫缺陷病毒的协同抑制作用。
Antimicrob Agents Chemother. 1987 Feb;31(2):168-72. doi: 10.1128/AAC.31.2.168.
Zotero 插件